Ionetix

Gallium-68

The first commercial ANDA approval for Gallium: Ga-68 PSMA-11, granted May 2026.

Ionetix became the first commercial drug manufacturer to receive ANDA approval for gallium Ga-68 gozetotide.

prostate-scan

Gallium Ga-68 gozetotide injection is a radioactive diagnostic agent indicated for positron emission tomography of prostate-specific membrane antigen positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or with suspected recurrence based on an elevated serum PSA level.

Ionetix has produced gallium-68 on the ION-12SC cyclotron and is pursuing production partnerships.

What is gallium Ga 68 gozetotide (PSMA-11)?

Gallium Ga 68 gozetotide, also known as Ga-68 PSMA-11, is a radioactive diagnostic agent for PET imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer, either with suspected metastasis who are candidates for initial definitive therapy, or with suspected recurrence based on an elevated serum PSA level.

What did the FDA approve for Ionetix in May 2026?

In May 2026 the FDA approved Ionetix’s Abbreviated New Drug Application (ANDA) for gallium Ga 68 gozetotide. Ionetix is the first commercial drug manufacturer to receive ANDA approval for the drug. Read the May 2026 announcement.

Has Ionetix produced gallium-68 on a cyclotron?

Yes. Ionetix has produced gallium-68 on its ION-12SC cyclotron and is pursuing production partnerships.

Important Safety Information for Gallium Ga 68 gozetotide injection

Indications and Usage

Gallium Ga 68 gozetotide injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

Warnings and Precautions

Risk for Misdiagnosis. Image interpretation errors can occur with gallium Ga 68 gozetotide PET. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of Gallium Ga 68 gozetotide injection for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of Gallium Ga 68 gozetotide injection for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score. Gallium Ga 68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget’s disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.

Radiation Risks. Gallium Ga 68 gozetotide injection contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and health care workers. Advise patients to hydrate before and after administration and to void frequently after administration.

Adverse Reactions

Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of Gallium Ga 68 gozetotide injection was evaluated in 960 patients, each receiving one dose of Gallium Ga 68 gozetotide injection. The average injected activity was 188.7 ± 40.7 MBq (5.1 ± 1.1 mCi).

The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of <1%.

Drug Interactions

Androgen deprivation therapy and other therapies targeting the androgen pathway. Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of gallium Ga 68 gozetotide PET has not been established.

Please note that this information is not a comprehensive list.

For full Prescribing Information, see the package insert on DailyMed.

Sites are encouraged to report any negative side effects of prescription drugs to the FDA. Visit FDA MedWatch or call 1-800-FDA-1088.

View Package Insert

Contact Ionetix.